KR101374458B1 - Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도 - Google Patents

Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도 Download PDF

Info

Publication number
KR101374458B1
KR101374458B1 KR1020087007797A KR20087007797A KR101374458B1 KR 101374458 B1 KR101374458 B1 KR 101374458B1 KR 1020087007797 A KR1020087007797 A KR 1020087007797A KR 20087007797 A KR20087007797 A KR 20087007797A KR 101374458 B1 KR101374458 B1 KR 101374458B1
Authority
KR
South Korea
Prior art keywords
formula
compound
group
fluoro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087007797A
Other languages
English (en)
Korean (ko)
Other versions
KR20080049090A (ko
Inventor
브라이언 부드직
데이비드 그윈 쿠퍼
이안 톰슨 포베스
빈센쪼 가르지아
지안 진
동추안 시
폴 윌리암 스미스
그라함 워커
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20080049090A publication Critical patent/KR20080049090A/ko
Application granted granted Critical
Publication of KR101374458B1 publication Critical patent/KR101374458B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020087007797A 2005-09-30 2006-09-27 Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도 Expired - Fee Related KR101374458B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0519950.0 2005-09-30
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds
GB0602040.8 2006-02-01
PCT/GB2006/003590 WO2007036715A2 (en) 2005-09-30 2006-09-27 Compounds which have activity at m1 receptor and their uses in medicine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137020049A Division KR20130091791A (ko) 2005-09-30 2006-09-27 Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도

Publications (2)

Publication Number Publication Date
KR20080049090A KR20080049090A (ko) 2008-06-03
KR101374458B1 true KR101374458B1 (ko) 2014-03-17

Family

ID=37598231

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087007797A Expired - Fee Related KR101374458B1 (ko) 2005-09-30 2006-09-27 Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도
KR1020137020049A Ceased KR20130091791A (ko) 2005-09-30 2006-09-27 Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137020049A Ceased KR20130091791A (ko) 2005-09-30 2006-09-27 Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도

Country Status (24)

Country Link
US (2) US8283364B2 (enExample)
EP (1) EP1943230B1 (enExample)
JP (1) JP5209480B2 (enExample)
KR (2) KR101374458B1 (enExample)
CN (1) CN101321736B (enExample)
AR (1) AR056103A1 (enExample)
AT (1) ATE492537T1 (enExample)
AU (1) AU2006296369B2 (enExample)
BR (1) BRPI0616609A2 (enExample)
CA (1) CA2624504C (enExample)
CR (1) CR9904A (enExample)
DE (1) DE602006019119D1 (enExample)
EA (1) EA016286B1 (enExample)
IL (1) IL190219A (enExample)
JO (1) JO2634B1 (enExample)
MA (1) MA29849B1 (enExample)
MY (1) MY148504A (enExample)
NO (1) NO20081945L (enExample)
NZ (1) NZ566508A (enExample)
PE (1) PE20070490A1 (enExample)
TW (1) TWI389905B (enExample)
UA (1) UA101299C2 (enExample)
WO (1) WO2007036715A2 (enExample)
ZA (1) ZA200802167B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036715A2 (en) 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US8288413B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
WO2007036718A2 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
US20170333407A1 (en) * 2014-11-03 2017-11-23 William Beaumont Hospital Method for treating underactive bladder syndrome
US10604484B2 (en) * 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
ES2865330T3 (es) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013262A1 (en) * 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
DE60013464T2 (de) 1999-10-13 2005-09-15 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
EP1263754A1 (en) 2000-02-01 2002-12-11 Millennium Pharmaceuticals, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
EP1975164B1 (en) 2001-04-18 2010-01-27 Euro-Celtique S.A. Octahydrobenzimidazolone compounds as analgetics
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
KR100809569B1 (ko) 2001-10-02 2008-03-04 아카디아 파마슈티칼스 인코포레이티드 무스카린 제제로서 벤즈이미다졸리디논 유도체
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
JP2005532361A (ja) 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
BRPI0412809A (pt) 2003-07-23 2006-09-26 Wyeth Corp compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
OA13248A (en) 2003-09-03 2007-01-31 Pfizer Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
ES2318556T3 (es) 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
US7300947B2 (en) 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
WO2007036715A2 (en) 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2007036718A2 (en) 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US8288413B2 (en) 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
CN101511222B (zh) 2006-09-08 2012-11-14 吉莱特公司 具有多种刷毛状态的牙刷
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013262A1 (en) * 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists

Also Published As

Publication number Publication date
IL190219A0 (en) 2008-11-03
ZA200802167B (en) 2009-08-26
UA101299C2 (uk) 2013-03-25
MA29849B1 (fr) 2008-10-03
JP2009512635A (ja) 2009-03-26
BRPI0616609A2 (pt) 2011-06-28
US8481566B2 (en) 2013-07-09
TW200806657A (en) 2008-02-01
CR9904A (es) 2008-07-29
JO2634B1 (en) 2012-06-17
EP1943230B1 (en) 2010-12-22
US20080255195A1 (en) 2008-10-16
DE602006019119D1 (de) 2011-02-03
AR056103A1 (es) 2007-09-19
JP5209480B2 (ja) 2013-06-12
TWI389905B (zh) 2013-03-21
MY148504A (en) 2013-04-30
CA2624504A1 (en) 2007-04-05
KR20130091791A (ko) 2013-08-19
AU2006296369A1 (en) 2007-04-05
EP1943230A2 (en) 2008-07-16
CA2624504C (en) 2014-07-08
ATE492537T1 (de) 2011-01-15
KR20080049090A (ko) 2008-06-03
EA200801001A1 (ru) 2008-08-29
US8283364B2 (en) 2012-10-09
EA016286B1 (ru) 2012-03-30
CN101321736B (zh) 2012-04-04
WO2007036715A3 (en) 2007-05-18
WO2007036715A2 (en) 2007-04-05
US20080058378A1 (en) 2008-03-06
NO20081945L (no) 2008-06-04
IL190219A (en) 2012-10-31
CN101321736A (zh) 2008-12-10
PE20070490A1 (es) 2007-05-30
AU2006296369B2 (en) 2012-12-20
NZ566508A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
US8481566B2 (en) Compounds which have activity at M1 receptor and their uses in medicine
JP5256187B2 (ja) Ｍ１受容体において活性を有するベンズイミダゾールおよび薬剤におけるそれらの使用
WO2008119720A1 (en) 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
JP5256189B2 (ja) Ｍ１受容体で活性を有するベンズイミダゾールおよび医薬におけるその使用
JP5209481B2 (ja) Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
JP5256188B2 (ja) Ｍ１受容体で活性を有するベンズイミダゾールおよび医薬におけるその使用
JP2010539218A (ja) Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用
JP5209479B2 (ja) Ｍ１受容体にて活性を有するベンゾイミダゾロン類
WO2008119717A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
WO2008119721A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
WO2008119715A1 (en) 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119711A1 (en) Substituted benzimidazolone compounds which have activity at m1 receptor and their uses in medicine
ES2357970T3 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina.
EP2344483B1 (en) Compounds which have activity at m1 receptor and their uses in medicine
JP2010539216A (ja) Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170308

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170308

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000